Carratù M R, DeSerio A, Mitolo-Chieppa D, Federico F
Institute of Pharmacology, Faculty of Medicine, University of Bari, Italy.
J Neural Transm Gen Sect. 1991;84(3):221-32. doi: 10.1007/BF01244972.
The ergot alkaloid derivatives, lisuride (LIS) and terguride (TDHL), known to interact with central dopamine receptors as agonist and partial agonist, respectively, were studied on the field-stimulated mouse vas deferens, where recently the existence of presynaptic dopamine receptors has been evidenced. LIS was a competitive antagonist at prejunctional alpha 2 and DA1 receptors situated on the sympathetic nerve terminals of the mouse, with a pA2 value of 9.2 and 9.1, respectively. LIS was also able to antagonize the effects of LY 171555, selective DA2 agonist, but the type of interaction cannot be conceptualized in terms of competitive antagonism. Likewise, the type of interaction of TDHL with dopaminergic and adrenergic agonist-activated sites is not suggestive of a competitive antagonism. Based on these results, it seems that central and peripheral pharmacologic profiles of LIS and TDHL cannot be overlapped, LIS being a potent DA1- and alpha 2-antagonist with a high degree of specifity for these receptors.
麦角生物碱衍生物利苏瑞(LIS)和特古瑞(TDHL),分别作为激动剂和部分激动剂与中枢多巴胺受体相互作用,在电场刺激的小鼠输精管上进行了研究,最近已证实该部位存在突触前多巴胺受体。LIS对位于小鼠交感神经末梢的突触前α2和DA1受体是竞争性拮抗剂,pA2值分别为9.2和9.1。LIS还能够拮抗选择性DA2激动剂LY 171555的作用,但这种相互作用的类型不能用竞争性拮抗来解释。同样,TDHL与多巴胺能和肾上腺素能激动剂激活位点的相互作用类型也不提示竞争性拮抗。基于这些结果,LIS和TDHL的中枢和外周药理学特征似乎无法重叠,LIS是一种强效的DA1和α2拮抗剂,对这些受体具有高度特异性。